Loading company
Just reported
From Illumina's results release of October 29, 2026; its quarterly report has since been filed.
Actual
$1.13B
+4.2% y/y
-2.6% q/q
Guided
—
No guide given
Actual
$1.43
+46% y/y
+5.9% q/q
Guided
—
No guide given
Actual
$305M
+34% y/y
+24% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Shares of revenue are estimates for quarter ended 2026-03-31, not figures from a filing.
NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.
StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.
Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.
Built from Illumina, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Illumina sells DNA-sequencing kits and machines to medical laboratories, hospitals, universities and drug companies.
Grade A+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Illumina, Inc.’s grade history. The other 39 go back to November 2016.
